Treatment and prognostic impact of transient leukemia in neonates with Down syndrome - PubMed (original) (raw)

Treatment and prognostic impact of transient leukemia in neonates with Down syndrome

Jan-Henning Klusmann et al. Blood. 2008.

Abstract

Approximately 10% of the neonates with Down syndrome (DS) exhibit a unique transient leukemia (TL). Though TL resolves spontaneously in most patients, early death and development of myeloid leukemia (ML-DS) may occur. Prognostic factors as well as treatment indication are currently uncertain. To resolve that issue, we prospectively collected clinical, biologic, and treatment data of 146 patients with TL. The 5-year overall survival (OS) and event-free survival (EFS) were 85% plus or minus 3% and 63% plus or minus 4%, respectively. Multivariate analysis revealed a correlation between high white blood cell (WBC) count, ascites, preterm delivery, bleeding diatheses, failure of spontaneous remission, and the occurrence of early death. Treatment with cytarabine (0.5-1.5 mg/kg) was administered to 28 patients with high WBC count, thrombocytopenia, or liver dysfunction. The therapy had a beneficial effect on the outcome of those children with risk factors for early death (5-year EFS, 52% +/- 12% vs 28% +/- 11% [no treatment]; P = .02). Multivariate analysis demonstrated its favorable prognostic impact. A total of 29 (23%) patients with TL subsequently developed ML-DS. Patients with ML-DS with a history of TL had a significantly better 5-year EFS (91% +/- 5%) than those without documented TL (70% +/- 4%), primarily due to a lower relapse rate. A history of TL may therefore define a lower-risk ML-DS subgroup. This study was registered at www.clinicaltrials.gov as no. NCT 00111345.

Trial registration: ClinicalTrials.gov NCT00111345.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Event-free and overall survival in children with Down syndrome and transient leukemia.

Figure 2

Figure 2

Significantly impaired prognosis in children with high WBC count at diagnosis. (A) EFS. (B) Cumulative incidence of death and ML-DS.

Figure 3

Figure 3

Cumulative incidence of death and of ML-DS in children with TL. Patients grouped according to the appearance of (A) ascites, (B) bleeding diatheses, (C) preterm delivery, and (D) pleural effusions.

Figure 4

Figure 4

Outcome of patients with TL with and without treatment with low-dose cytarabine. (A) EFS of those patients with TL with high WBC count, ascites, preterm delivery, and bleeding diatheses and without spontaneous remission. (B) Cumulative incidence of death.

Figure 5

Figure 5

EFS in children with ML-DS and a history of TL compared with those with ML-DS and no history of TL (enrolled between 1993 and 2006).

Similar articles

Cited by

References

    1. Creutzig U, Ritter J, Vormoor J, et al. Transient myeloproliferative disorders and acute leukaemias in infants with Down's syndrome. Contrib Oncol. 1990;41:75–84.
    1. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–2131. - PubMed
    1. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126–134. - PubMed
    1. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–4613. - PubMed
    1. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392–399. - PubMed

Publication types

MeSH terms

LinkOut - more resources